Nulibry

Chemical Namefosdenopterin
Dosage FormInjection (intravenous; 9.5 mg)
Drug ClassMiscellaneous
SystemNervous
CompanyAlcami Carolinas Corporation
Approval Year2021

Indication

  • Indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.
Last updated on 3/4/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nulibry (fosdenopterin) Prescribing Information2021Alcami Carolinas Corporation, Charleston, SC